For example, elevated levels of IL-6 stimulate hyperactivation of JAK/STAT3 signaling, which is often associated with poor patient outcomes in colorectal cancer (32), breast cancer (33), oral cancer (34), and myeloma (35). This evidence concerns the gene IL6 and plasma cell myeloma.